Search - tctmd.com

Displaying 1 - 20 of 60

Sort: Relevancy | Date

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

Michael O'Riordan

December 01, 2016

News Daily News

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Yael L. Maxwell

September 14, 2016

News Daily News

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

Yael L. Maxwell

September 14, 2016

News Daily News

El Abciximab Intracoronario es Beneficioso en Pacientes Diabéticos Víctimas de STEMI

L.A. McKeown

August 11, 2016

News Daily News

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

L.A. McKeown

August 04, 2016

News Daily News

Los Niveles Altos de Lípidos Dictados Genéticamente Parecen Proteger Frente a la Diabetes Tipo 2

Todd Neale

August 04, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Todd Neale

July 06, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Caitlin E. Cox

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Yael L. Maxwell

May 13, 2016

News Daily News

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Michael O'Riordan

March 25, 2016

News Daily News

Sweet Surrender? Trimming Sweetness from Sugary Drinks May Cut Obesity-Related Diseases

Todd Neale

January 06, 2016

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

Advertisement

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Las Variantes del Gen PCSK9 se asocian a Niveles Más Bajos de Colesterol LBD y a un Mayor Riesgo de Diabetes

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Infective Endocarditis After TAVR Linked to Diabetes, Residual Aortic Regurgitation in Large Registry

El Abciximab Intracoronario es Beneficioso en Pacientes Diabéticos Víctimas de STEMI

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

Los Niveles Altos de Lípidos Dictados Genéticamente Parecen Proteger Frente a la Diabetes Tipo 2

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Los Fibroateromas de Casquete Fino Podrían Explicar los Malos Resultados PCI de los Pacientes Diabéticos

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Sweet Surrender? Trimming Sweetness from Sugary Drinks May Cut Obesity-Related Diseases

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content